Aarhus University

At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.

Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.

Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.